PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-61.84%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-45.56%
Operating expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-45.56%
Total costs reduction while Biotechnology median is -0.03%. Seth Klarman would investigate advantages.
8.78%
Interest expense change of 8.78% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
45.56%
EBITDA change of 45.56% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
45.56%
Income change of 45.56% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% versus flat Biotechnology. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.89%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
30.89%
Income change of 30.89% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
30.77%
EPS growth exceeding 1.5x Biotechnology median of 1.22%. Joel Greenblatt would investigate advantages.
30.77%
Diluted EPS growth exceeding 1.5x Biotechnology median of 1.22%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.